Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxue Tongjiang
- Development stage
- Unknown
- Lead developer
- Tianshili Pharmaceutical Group
- Administration
- Oral
01
Overview
Huoxue Tongjiang is a patented Traditional Chinese Medicine (TCM) formula composed of multiple herbal ingredients. It is being investigated for the treatment of non-erosive reflux disease (NERD), reflux esophagitis, and Barrett's esophagus, particularly in patients presenting with Qi stagnation-blood stasis syndrome. The drug is administered orally in granule form and has demonstrated anti-inflammatory effects and the ability to promote esophageal motility.
- Other names
- Huoxue Tongjiang granulesHuoxue Tongjiang Formula GranulesHuoxue Tongjiang DecoctionHuoxue Tongjiang Prescription
02
Targets
IL10 (Interleukin-10)IL-6 (Interleukin 6)TP53 (Cellular Tumor Antigen p53 R175H)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on Huoxue Tongjiang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huoxue Tongjiang.